ubstitute for form 1449A/PTO

NOV 0 6 2002

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

a plus sign (+)	inside this b	6 <del>2-4</del> /		3	PTO/SB/08/		
			A)	pproved for use through 10/31. lemark Office: U.S. DEPARTN	2002. OMB 06	51-0031	<u>'</u>
Under the Par	erwork Reduc	ction Act of 1995, no persons	are required to respond to a collection of	of information unless it contains a	ralid OMB	INERCE Inumber	
for form 1449A				C mplet if Kn wn			\ <u>&amp;</u>
			Application Number	10/067,996	<del></del>	00	8
RMATIC	ON DIS	CLOSURE	Filing Date	February 8, 2002		~	9
<b>EMENT</b>	BY AI	PPLICANT	First Named Inventor	Allen T. Hopper	Ш		œ
			Group Art Unit	Unassgined	()		F
use as many	sheets as	necessary)	Examiner Name	Unassigned		0	颠
1	of	2	Attorney Docket Number	MEMORY-2	~ H	2	呈
•							$\overline{\mathbf{S}}$
		U.S. P	ATENT DOCUMENTS				<b> =</b>
1							1

U.S. PATENT DOCUMENTS								
Examiner Initials *	Cite No.1	U.S. Patent Docum  Number Kind Co  (if know	de <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Releva Passages or Relevant Figures Appear		
KI	1	5,013,829		NAIR et al.	05-07-1991			
	<u> </u>				- · · · · · · · · · · · · · · · · · · ·	;		
						:		
	<u> </u>	-	-			·		
	ļ					:		
	ļ							
	ļ	-						
					· · · · · · · · · · · · · · · · · · ·			
	<del> </del>							
	1	<del>                                     </del>	-					
••		† ··· · · · · · · · · · · · · · · · · ·		~				
-				*		•		
						·		
						•		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document  Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		Foreign Patent Document  Name of Patentee  Or Applicant of  Cited Document  AMA DO		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
							*	
			İ					
		<u> </u>						
		<u> </u>					:	
		ļ <u>.</u>			·			
	l	1		i				

Examiner Signature	At Chy No	app	Date Considered	June 12, 2003	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 

Applicant is to place a check mark hee if English language Translation is

NOV 0 6 2002



PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete if Known			
INICO	DRAKTION	DIE	CLOCUBE	Application Number	10/067,996		
			CLOSURE	Filing Date	February 8, 2002		
STATEMENT BY APPLICANT				First Named Inventor	Allen T. Hopper		
\				Group Art Unit	Unassgined		
`	(use as many she	ets as	necessary)	Examiner Name	Unassigned		
Sheet	2	of	2	Attorney Docket Number	MEMORY-2		

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
KN	2	THOMAS C. MCKENZIE et al., "The Gomberg-Bachmann Reaction of Purines", <u>J. Heterocyclic Chem.,</u> May-Jun 1987, pp. 859-861, Vol. 24	
	3	VASU NAIR et al., "Novel, Stable Congeners of Antiretroviral Compound 2', 3'- Dideoxyadenosine," J. Am. Chem. Soc., 1989, pp. 8502-8504, Vol. 111	
	4	JAMES E. KELLEY et al., "Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," <u>Eur. J. Med. Chem.</u> , 1990, pp. 131-135, Vol. 25	
	5	JEAN-JACQUES BOURGUIGNON et al., *9-Benzyladenines: Potent and Selective cAMP Phosphodiesterase Inhibitors,* J. Med. Chem, 1997, pp. 1768-1770, Vol. 40	
	6	JAMES L. KELLEY et al., "6-(Alkylamino)-9-alkylpurines. A New Class of Potential Antipsychotic Agents," J. Med. Chem., 1997, pp. 3207-3216, Vol. 40	
	7	ELISABETH BOICHOT et al., "Anti-Inflammatory Activities of a New Series of Selective Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine," The Journal Of Pharmacology And Experimental Therapeutics, 2000, pp. 647-653, Vol 292, No.2	
	8	V. VAIR, "Hydrolysis of Dideoxgenated Purine Nucleosides: Effect of Modification of the Base Moiety", <u>J. ORG.</u> <u>CHEM</u> , 1990, pp. 3695-3697, vol. 55, no. 11	
	9	H. NAGANO et al., "Fluorine-Containing Potential Anticancer agents. II. Syntheses Trifuoromethylpurines and Trifluormethylthiazolopyrimidines", <u>J. MED. CHEM.</u> , 1964, pp. 215-220, vol. 7, no. 2	
	10	VASU NAIR et al., "Inhibition of mammalian adenosine deaminase by novel functionalized 2', 3'-dideoxyadenosines", <u>BIOCHIM. BIOPHYS. ACTA.</u> 1991, pp. 121-123, vol. 1078, no. 1	
	11	PATENT ABSTRACTS OF JAPAN, vol. 2000, no. 6, September 22, 2000, JP 200 072773, March 7, 2000	
V_	12	PATENT ABSTRACTS OF JAPAN, vol. 1999, no. 12, October 29, 1999, JP 11 180982, July 6, 1999	
		<u>:</u>	

Examiner Signature Styles Was	Date Considered	June 12, 203
-------------------------------	--------------------	--------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
NOV 0 7 2002
TECH CENTER 1600/2900

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.